Apogee Therapeutics Inc [APGE] stock is trading at $39.74, up 0.40%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The APGE shares have gain 11.72% over the last week, with a monthly amount glided 24.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apogee Therapeutics Inc [NASDAQ: APGE] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $95. Previously, Canaccord Genuity started tracking the stock with Buy rating on November 25, 2024, and set its price target to $89. On May 10, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $80 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $43 on December 20, 2023. Wedbush initiated its recommendation with a Outperform and recommended $40 as its price target on August 08, 2023. In a note dated August 08, 2023, Stifel initiated an Buy rating and provided a target price of $34 on this stock.
Apogee Therapeutics Inc [APGE] stock has fluctuated between $26.20 and $63.50 over the past year. Currently, Wall Street analysts expect the stock to reach $95 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $39.74 at the most recent close of the market. An investor can expect a potential return of 139.05% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.19 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.36 points at the first support level, and at 36.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 40.58, and for the 2nd resistance point, it is at 41.42.
Ratios To Look Out For
For context, Apogee Therapeutics Inc’s Current Ratio is 15.82. As well, the Quick Ratio is 15.82, while the Cash Ratio is 3.24.
Transactions by insiders
Recent insider trading involved Dambkowski Carl, Chief Medical Officer, that happened on May 07 ’25 when 2725.0 shares were sold. Chief Medical Officer, Dambkowski Carl completed a deal on Apr 02 ’25 to sell 3860.0 shares. Meanwhile, Officer CARL DAMBKOWSKI bought 9310.0 shares on Apr 02 ’25.
